| Year |
Citation |
Score |
| 2023 |
Ratliff T, Cooper P, Yang J, Wang HH, Broman M, Awdalkreem G, Cresswell G, Wang L, Goossens E, Atallah-Lanman N, Doerge R, Zheng F, Cheng L, Crist S, Braun R, et al. Inflammation Impacts Androgen Receptor Signaling in Basal Prostate Stem Cells Through Interleukin 1 Receptor Antagonist. Research Square. PMID 38168414 DOI: 10.21203/rs.3.rs-3539806/v1 |
0.342 |
|
| 2022 |
Calvert RD, Fleet JC, Fournier PGJ, Juarez P, Burcham GN, Haverkamp JM, Guise TA, Ratliff TL, Elzey BD. Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. Immunohorizons. 6: 790-806. PMID 36480485 DOI: 10.4049/immunohorizons.2200079 |
0.768 |
|
| 2022 |
Vickman RE, Aaron-Brooks L, Zhang R, Lanman NA, Lapin B, Gil V, Greenberg M, Sasaki T, Cresswell GM, Broman MM, Paez JS, Petkewicz J, Talaty P, Helfand BT, Glaser AP, ... ... Ratliff TL, et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nature Communications. 13: 2133. PMID 35440548 DOI: 10.1038/s41467-022-29719-1 |
0.359 |
|
| 2022 |
Owens JL, Beketova E, Liu S, Shen Q, Pawar JS, Asberry AM, Yang J, Deng X, Elzey BD, Ratliff TL, Cheng L, Choo CR, Citrin DE, Polascik TJ, Wang B, et al. Targeting protein arginine methyltransferase 5 (PRMT5) suppresses radiation-induced neuroendocrine differentiation and sensitizes prostate cancer cells to radiation. Molecular Cancer Therapeutics. PMID 35027481 DOI: 10.1158/1535-7163.MCT-21-0103 |
0.41 |
|
| 2021 |
Farah E, Zhang Z, Utturkar SM, Liu J, Ratliff TL, Liu X. Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer. Molecular Cancer Therapeutics. 21: 193-205. PMID 34728570 DOI: 10.1158/1535-7163.MCT-21-0581 |
0.346 |
|
| 2020 |
Wu J, Lee HJ, You L, Luo X, Hasegawa T, Huang KC, Lin P, Ratliff T, Ashizawa M, Mei J, Cheng JX. Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer. Small (Weinheim An Der Bergstrasse, Germany). e2001215. PMID 32307923 DOI: 10.1002/Smll.202001215 |
0.455 |
|
| 2020 |
Vickman R, Cresswell G, Lanman N, Broman M, Franco O, Helfand B, Glaser A, Katz L, Petkewicz J, Talaty P, Crawford S, Ratliff T, Hayward* S. MP06-11 CHARACTERIZATION OF INFLAMMATORY CELLS IN HUMAN BENIGN PROSTATIC HYPERPLASIA The Journal of Urology. 203: e55. DOI: 10.1097/Ju.0000000000000820.011 |
0.468 |
|
| 2019 |
Knapp DW, Dhawan D, Ramos-Vara JA, Ratliff TL, Cresswell GM, Utturkar S, Sommer BC, Fulkerson CM, Hahn NM. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. Frontiers in Oncology. 9: 1493. PMID 32039002 DOI: 10.3389/Fonc.2019.01493 |
0.323 |
|
| 2019 |
Fleet JC, Burcham GN, Calvert RD, Elzey BD, Ratliff TL. 1α, 25 Dihydroxyvitamin D (1,25(OH)D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). The Journal of Steroid Biochemistry and Molecular Biology. 198: 105557. PMID 31783150 DOI: 10.1016/J.Jsbmb.2019.105557 |
0.325 |
|
| 2019 |
Vickman RE, Broman MM, Lanman NA, Franco OE, Sudyanti PAG, Ni Y, Ji Y, Helfand BT, Petkewicz J, Paterakos MC, Crawford SE, Ratliff TL, Hayward SW. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. The Prostate. PMID 31763714 DOI: 10.1002/Pros.23929 |
0.467 |
|
| 2019 |
Taha MS, Cresswell GM, Park J, Lee W, Ratliff TL, Yeo Y. Sustained delivery of carfilzomib by tannic acid-based nanocapsules helps develop antitumor immunity. Nano Letters. PMID 31657935 DOI: 10.1021/Acs.Nanolett.9B04147 |
0.382 |
|
| 2019 |
Jack S, Madhivanan K, Ramadesikan S, Subramanian S, Edwards DF, Elzey BD, Dhawan D, McCluskey A, Kischuk EM, Loftis AR, Truex N, Santos M, Lu M, Rabideau A, Pentelute B, ... ... Ratliff TL, et al. A Novel, Safe, Fast, Efficient Treatment for Her2-positive and Negative Bladder Cancer Utilizing an EGF-Anthrax Toxin Chimera. International Journal of Cancer. PMID 31584195 DOI: 10.1002/Ijc.32719 |
0.378 |
|
| 2019 |
Yang J, Broman MM, Cooper PO, Lanman NA, Strand DW, Morrissey C, Ratliff TL. Distinct expression patterns of SULT2B1b in human prostate epithelium. The Prostate. PMID 31212370 DOI: 10.1002/Pros.23829 |
0.465 |
|
| 2019 |
Farah E, Li C, Cheng L, Kong Y, Lanman NA, Pascuzzi PE, Lorenz GR, Zhang Y, Ahmad N, Li L, Ratliff T, Liu X. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. The Journal of Biological Chemistry. PMID 30940724 DOI: 10.1074/Jbc.Ra118.006983 |
0.432 |
|
| 2019 |
Vickman RE, Yang J, Lanman NA, Cresswell GM, Zheng F, Zhang C, Doerge RW, Crist SA, Mesecar AD, Hu CD, Ratliff TL. Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNF alpha in Castration Resistant Prostate Cancer. Molecular Cancer Research : McR. PMID 30824526 DOI: 10.1158/1541-7786.Mcr-18-1054 |
0.493 |
|
| 2019 |
Nikhil K, Chang L, Viccaro K, Jacobsen M, McGuire C, Satapathy SR, Tandiary M, Broman MM, Cresswell G, He YJ, Sandusky GE, Ratliff TL, Chowdhury D, Shah K. Identification of LIMK2 as a Therapeutic Target in Castration Resistant Prostate Cancer. Cancer Letters. PMID 30716360 DOI: 10.1016/J.Canlet.2019.01.035 |
0.48 |
|
| 2019 |
Fleet JC, Burcham GN, Calvert R, Ratliff TL. Abstract 2364: 1α, 25 dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor sells (MDSC) Cancer Research. 79: 2364-2364. DOI: 10.1158/1538-7445.Am2019-2364 |
0.346 |
|
| 2018 |
Orillion AR, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti HC, Elbanna M, Chintala S, Ciesielski MJ, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia DJ, Abrams SI, et al. Dietary protein restriction reprograms tumor associated macrophages and enhances immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190370 DOI: 10.1158/1078-0432.Ccr-18-0980 |
0.304 |
|
| 2018 |
Lee HJ, Li J, Vickman RE, Li J, Liu R, Durkes A, Elzey BD, Yue S, Liu X, Ratliff TL, Cheng JX. Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway. Molecular Cancer Research : McR. PMID 29545473 DOI: 10.1158/1541-7786.Mcr-17-0665 |
0.444 |
|
| 2018 |
Vickman RE, Broman MM, Atallah NM, Sudyanti A, Franco OE, Ratliff TL, Hayward SW. Abstract 5075: Single-cell RNAseq of human prostate cancer-associated fibroblasts reveals distinct subpopulations that may promote inflammatory cell recruitment to the tumor microenvironment Tumor Biology. DOI: 10.1158/1538-7445.Am2018-5075 |
0.497 |
|
| 2018 |
Kischuk E, Majumder J, Fine JA, Lantz TC, Dhawan D, Knapp DW, Ratliff TL, Chopra G. Abstract 4709: Cell-specific gene program-based small-molecule immunomodulators targeting solid-tumor microenvironments Cancer Research. 78: 4709-4709. DOI: 10.1158/1538-7445.Am2018-4709 |
0.393 |
|
| 2018 |
Cooper P, Wang H, Broman M, Goossens E, Kaimakliotis H, Crist S, Atallah N, Kazemian M, Elzey B, Cheng L, Ratliff TL. 2185 The effects of autoimmune inflammation on proliferation, differentiation, and androgen receptor signaling in adult prostate stem cells Journal of Clinical and Translational Science. 2: 31-31. DOI: 10.1017/cts.2018.132 |
0.394 |
|
| 2017 |
Mirsaidi N, Burns MP, McClain SA, Forsyth E, Li J, Dukes B, Lin D, Nahvi R, Giraldo J, Patton M, Wang P, Lin K, Miller E, Ratliff T, Hamidi S, et al. Enhanced Mortality to Metastatic Bladder Cancer Cell Line MB49 in Vasoactive Intestinal Peptide Gene Knockout Mice. Frontiers in Endocrinology. 8: 162. PMID 28824540 DOI: 10.3389/Fendo.2017.00162 |
0.313 |
|
| 2017 |
Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM, Knapp DW. Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. International Journal of Genomics. 2017: 6589529. PMID 28487862 DOI: 10.1155/2017/6589529 |
0.34 |
|
| 2017 |
Liu X, Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL. Targeting Plk1 to enhance efficacy of Olaparib in castration-resistant prostate cancer. Molecular Cancer Therapeutics. PMID 28069876 DOI: 10.1158/1535-7163.Mct-16-0361 |
0.423 |
|
| 2017 |
Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA. Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device. Lab On a Chip. PMID 28054089 DOI: 10.1039/C6Lc01279E |
0.456 |
|
| 2017 |
Cooper P, Wang H, Broman M, Kaimakliotis H, Elzey B, Crist S, Cheng L, Ratliff T. 2279 Journal of Clinical and Translational Science. 1: 60-60. DOI: 10.1017/cts.2017.216 |
0.391 |
|
| 2016 |
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical: Trial of 6,630 Men. The Journal of Urology. PMID 28012755 DOI: 10.1016/J.Juro.2016.10.073 |
0.454 |
|
| 2016 |
Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J, Hu CD. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene. PMID 27546619 DOI: 10.1038/Onc.2016.287 |
0.477 |
|
| 2016 |
Vickman RE, Crist SA, Kerian K, Eberlin L, Cooks RG, Burcham GN, Buhman KK, Hu CD, Mesecar AD, Cheng L, Ratliff TL. Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. Molecular Cancer Research : McR. PMID 27341831 DOI: 10.1158/1541-7786.Mcr-16-0137 |
0.474 |
|
| 2016 |
Li J, Gu D, Lee SS, Song B, Bandyopadhyay S, Chen S, Konieczny SF, Ratliff TL, Liu X, Xie J, Cheng JX. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. PMID 27132508 DOI: 10.1038/Onc.2016.168 |
0.318 |
|
| 2015 |
Cimen Bozkus C, Elzey BD, Crist SA, Ellies LG, Ratliff TL. Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity. Journal of Immunology (Baltimore, Md. : 1950). 195: 5237-50. PMID 26491198 DOI: 10.4049/Jimmunol.1500959 |
0.414 |
|
| 2015 |
Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X. Co-targeting Polo-like kinase 1(Plk1) and the Wnt/β-catenin signaling pathway in castration-resistant prostate cancer. Molecular and Cellular Biology. PMID 26438599 DOI: 10.1128/Mcb.00825-15 |
0.385 |
|
| 2015 |
Wang HH, Wang L, Jerde TJ, Chan BD, Savran CA, Burcham GN, Crist S, Ratliff TL. Characterization of autoimmune inflammation induced prostate stem cell expansion. The Prostate. PMID 26174474 DOI: 10.1002/Pros.23043 |
0.489 |
|
| 2015 |
Wang L, Zoetemelk M, Chitteti BR, Ratliff TL, Myers JD, Srour EF, Broxmeyer H, Jerde TJ. Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate. American Journal of Physiology. Renal Physiology. 308: F1421-30. PMID 25925259 DOI: 10.1152/Ajprenal.00488.2014 |
0.495 |
|
| 2015 |
Lee SS, Li J, Tai JN, Ratliff TL, Park K, Cheng JX. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. Acs Nano. 9: 2420-32. PMID 25662106 DOI: 10.1021/Nn504025A |
0.398 |
|
| 2015 |
Shao C, Ahmad N, Hodges K, Kuang S, Ratliff T, Liu X. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. The Journal of Biological Chemistry. 290: 2024-33. PMID 25505174 DOI: 10.1074/Jbc.M114.596817 |
0.445 |
|
| 2015 |
Lee HJ, Yue S, Li J, Lee S, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL, Cheng J. Abstract A06: Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A06 |
0.459 |
|
| 2015 |
Li J, Lee S, Gu D, Song B, Chen S, Konieczny S, Ratliff T, Liu X, Xie J, Cheng J. Abstract B50: Abrogating cholesterol esterification suppresses pancreatic cancer growth and metastasis mediated by caveolin-1 Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B50 |
0.325 |
|
| 2014 |
Burcham GN, Cresswell GM, Snyder PW, Chen L, Liu X, Crist SA, Henry MD, Ratliff TL. Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis. The American Journal of Pathology. 184: 3176-91. PMID 25455686 DOI: 10.1016/J.Ajpath.2014.08.021 |
0.476 |
|
| 2014 |
Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Research. 74: 6635-47. PMID 25252916 DOI: 10.1158/0008-5472.Can-14-1916 |
0.454 |
|
| 2014 |
Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL, Cheng JX. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metabolism. 19: 393-406. PMID 24606897 DOI: 10.1016/J.Cmet.2014.01.019 |
0.466 |
|
| 2013 |
Crist SA, Elzey BD, Ahmann MT, Ratliff TL. Early growth response-1 (EGR-1) and nuclear factor of activated T cells (NFAT) cooperate to mediate CD40L expression in megakaryocytes and platelets. The Journal of Biological Chemistry. 288: 33985-96. PMID 24106272 DOI: 10.1074/Jbc.M113.511881 |
0.315 |
|
| 2013 |
Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, Ratliff T, Liu X. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. The Prostate. 73: 1352-63. PMID 23661607 DOI: 10.1002/Pros.22683 |
0.445 |
|
| 2013 |
Gardner TA, Fletcher JW, Ko S, Low PS, Ratliff TL. Abstract LB-90: DUPA-99mTc localizes to prostate cancer in men with locally advanced and metastatic disease. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-90 |
0.425 |
|
| 2013 |
Yue S, Li J, Lee SY, Shao T, Song B, Cheng L, Hu C, Liu X, Ratliff TL, Cheng J. Abstract 1893: Spectroscopic imaging unveils altered cholesterol metabolism in prostate cancer . Cancer Research. 73: 1893-1893. DOI: 10.1158/1538-7445.Am2013-1893 |
0.454 |
|
| 2013 |
Gardner T, Fletcher J, Ko S, Green M, Hutchins G, Koch M, Tann M, Low P, Ratliff T. 2026 PHASE 0 TRIAL OF DUPA-
99M
TC IMAGING IN MEN WITH METASTATIC PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2445 |
0.407 |
|
| 2012 |
Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD. Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. Journal of Immunology (Baltimore, Md. : 1950). 189: 3936-46. PMID 22984076 DOI: 10.4049/Jimmunol.1201415 |
0.472 |
|
| 2012 |
Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, Fitzgerald T, Butterfield J, Charbonneau B, Violette SM, Weinreb PH, Ratliff TL, Liao CP, Roy-Burman P, Vietri M, Lian JB, et al. α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. American Journal of Translational Research. 4: 165-74. PMID 22611469 |
0.78 |
|
| 2012 |
Coon BG, Crist S, González-Bonet AM, Kim HK, Sowa J, Thompson DH, Ratliff TL, Aguilar RC. Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells. International Journal of Cancer. Journal International Du Cancer. 131: 591-600. PMID 21901746 DOI: 10.1002/Ijc.26413 |
0.367 |
|
| 2012 |
Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Liu X. Abstract 233: Polo-like kinase 1 facilitates loss of Pten-induced prostate cancer formation Cancer Research. 72: 233-233. DOI: 10.1158/1538-7445.Am2012-233 |
0.505 |
|
| 2011 |
Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, Ratliff TL, Hu CD. Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. American Journal of Cancer Research. 1: 834-44. PMID 22016831 |
0.398 |
|
| 2011 |
Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Ahmad N, Liu X. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. The Journal of Biological Chemistry. 286: 35795-800. PMID 21890624 DOI: 10.1074/Jbc.C111.269050 |
0.501 |
|
| 2011 |
Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. The American Journal of Pathology. 179: 502-12. PMID 21703427 DOI: 10.1016/J.Ajpath.2011.03.014 |
0.81 |
|
| 2011 |
Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson RU, Henry MD, Wang HH, Ratliff TL. An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. The Prostate. 71: 1139-50. PMID 21656824 DOI: 10.1002/Pros.21327 |
0.785 |
|
| 2011 |
Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. European Journal of Immunology. 41: 749-59. PMID 21287554 DOI: 10.1002/Eji.201041069 |
0.796 |
|
| 2011 |
Wang X, Zhao M, Nolte DD, Ratliff TL. Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array. Biosensors & Bioelectronics. 26: 1871-5. PMID 20236816 DOI: 10.1016/J.Bios.2010.02.009 |
0.359 |
|
| 2010 |
Eberlin LS, Dill AL, Costa AB, Ifa DR, Cheng L, Masterson T, Koch M, Ratliff TL, Cooks RG. Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Analytical Chemistry. 82: 3430-4. PMID 20373810 DOI: 10.1021/Ac9029482 |
0.397 |
|
| 2010 |
Hu C, Elzey B, Poulson J, Morrison W, Deng X, Torregrosa-Allen S, Ratliff T. 375 RADIATION INDUCES NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER CELL LINES
IN VITRO
AND
IN VIVO Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.443 |
0.451 |
|
| 2009 |
Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7375-80. PMID 19920098 DOI: 10.1158/1078-0432.Ccr-09-1910 |
0.386 |
|
| 2009 |
Sowa JM, Crist SA, Ratliff TL, Elzey BD. Platelet influence on T- and B-cell responses. Archivum Immunologiae Et Therapiae Experimentalis. 57: 235-41. PMID 19578816 DOI: 10.1007/S00005-009-0032-Y |
0.33 |
|
| 2008 |
Elzey BD, Schmidt NW, Crist SA, Kresowik TP, Harty JT, Nieswandt B, Ratliff TL. Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood. 111: 3684-91. PMID 18256321 DOI: 10.1182/Blood-2007-05-091728 |
0.331 |
|
| 2008 |
Crist SA, Sprague DL, Ratliff TL. Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood. 111: 3553-61. PMID 18180380 DOI: 10.1182/Blood-2007-05-088161 |
0.312 |
|
| 2008 |
Haverkamp J, Charbonneau B, Ratliff TL. Prostate inflammation and its potential impact on prostate cancer: a current review. Journal of Cellular Biochemistry. 103: 1344-53. PMID 17955503 DOI: 10.1002/Jcb.21536 |
0.786 |
|
| 2008 |
Sinn HW, Elzey BD, Jensen RJ, Zhao X, Zhao W, Ratliff TL. The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity. Cancer Immunology, Immunotherapy : Cii. 57: 573-9. PMID 17786441 DOI: 10.1007/S00262-007-0397-X |
0.309 |
|
| 2008 |
Griffith TS, Konety BR, Joudi FN, Madsen T, Ziegler B, Cohen MB, Ratliff TL, Williams RD. PHASE I TRIAL OF Ad5-TRAIL-MEDIATED GENE TRANSFER IN MEN WITH LOCALLY-CONFINED PROSTATE CANCER PRIOR TO PLANNED RADICAL PROSTATECTOMY Journal of Urology. 179: 396-396. DOI: 10.1016/S0022-5347(08)61160-X |
0.402 |
|
| 2008 |
Lubaroff DM, Konety BR, Link BK, Ratliff TL, Madsen T, Williams RD. OUTCOMES FROM A PHASE I TRIAL OF AN ADENOVIRUS/PSA VACCINE FOR PROSTATE CANCER Journal of Urology. 179: 184-184. DOI: 10.1016/S0022-5347(08)60534-0 |
0.393 |
|
| 2007 |
Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. Journal of Immunology (Baltimore, Md. : 1950). 179: 7244-53. PMID 18025166 DOI: 10.4049/Jimmunol.179.11.7244 |
0.742 |
|
| 2007 |
Sprague DL, Sowa JM, Elzey BD, Ratliff TL. The role of platelet CD154 in the modulation in adaptive immunity. Immunologic Research. 39: 185-93. PMID 17917065 DOI: 10.1007/S12026-007-0074-3 |
0.32 |
|
| 2006 |
Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, Ratliff TL. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. International Journal of Cancer. 119: 2632-41. PMID 16991124 DOI: 10.1002/Ijc.22220 |
0.695 |
|
| 2006 |
Lubaroff DM, Konety B, Link BK, Ratliff TL, Madsen T, Shannon M, Ecklund D, Williams RD. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Human Gene Therapy. 17: 220-9. PMID 16454655 DOI: 10.1089/Hum.2006.17.220 |
0.455 |
|
| 2006 |
Lees JR, Charbonneau B, Swanson AK, Jensen R, Zhang J, Matusik R, Ratliff TL. Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology. 117: 248-61. PMID 16423061 DOI: 10.1111/J.1365-2567.2005.02293.X |
0.796 |
|
| 2006 |
Lees JR, Charbonneau B, Hayball JD, Diener K, Brown M, Matusik R, Cohen MB, Ratliff TL. T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. The Prostate. 66: 578-90. PMID 16388504 DOI: 10.1002/Pros.20307 |
0.811 |
|
| 2006 |
Ratliff TL. Detection of Prostate Cancer With a Blood-Based Assay for Early Prostate Cancer Antigen The Journal of Urology. 175: 389. DOI: 10.1097/00005392-200601000-00129 |
0.469 |
|
| 2006 |
Ratliff TL. Caveolin-1 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer: Genetic Ablation of Cav-1 Delays Advanced Prostate Tumor Development in Tramp Mice The Journal of Urology. 175. DOI: 10.1097/00005392-200601000-00128 |
0.478 |
|
| 2006 |
Ratliff TL. A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs and Prostate Cancer Incidence The Journal of Urology. 175: 388. DOI: 10.1097/00005392-200601000-00127 |
0.419 |
|
| 2006 |
Ratliff TL. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer: Commentary Journal of Urology. 175: 1171. DOI: 10.1016/S0022-5347(05)00625-7 |
0.353 |
|
| 2006 |
Ratliff TL. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen: Commentary Journal of Urology. 175: 389. DOI: 10.1016/S0022-5347(05)00111-4 |
0.366 |
|
| 2006 |
Ratliff TL. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice - Commentary Journal of Urology. 175: 388-389. DOI: 10.1016/S0022-5347(05)00110-2 |
0.376 |
|
| 2006 |
Ratliff TL. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence: Commentary Journal of Urology. 175: 388. DOI: 10.1016/S0022-5347(05)00109-6 |
0.305 |
|
| 2005 |
Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cellular Immunology. 238: 1-9. PMID 16442516 DOI: 10.1016/J.Cellimm.2005.12.005 |
0.313 |
|
| 2005 |
Ratliff TL. Urine markers for bladder cancer surveillance: a systematic review. The Journal of Urology. 174: 2065-6. PMID 16217395 DOI: 10.1016/S0022-5347(01)68890-6 |
0.3 |
|
| 2005 |
Ratliff TL. Estrogen receptor alpha and imprinting of the neonatal mouse ventral prostate by estrogen. The Journal of Urology. 174: 1149. PMID 16094084 DOI: 10.1097/01.Ju.0000171853.20105.60 |
0.358 |
|
| 2005 |
Ratliff TL. Mutation of the androgen receptor causes oncogenic transformation of the prostate. The Journal of Urology. 174: 1149. PMID 16094083 DOI: 10.1016/S0022-5347(01)68543-4 |
0.382 |
|
| 2005 |
Ratliff TL. Agents in development for prostate cancer prevention. The Journal of Urology. 174: 788. PMID 16006979 DOI: 10.1016/S0022-5347(01)68394-0 |
0.448 |
|
| 2005 |
Ratliff TL. High molecular mass proteome of androgen-independent prostate cancer. The Journal of Urology. 174: 787. PMID 16006978 DOI: 10.1097/01.Ju.0000170978.75277.36 |
0.442 |
|
| 2005 |
Elzey BD, Grant JF, Sinn HW, Nieswandt B, Waldschmidt TJ, Ratliff TL. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. Journal of Leukocyte Biology. 78: 80-4. PMID 15899982 DOI: 10.1189/Jlb.1104669 |
0.65 |
|
| 2005 |
Ratliff TL. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. The Journal of Urology. 173: 1045. PMID 15711375 DOI: 10.1016/S0022-5347(05)60440-5 |
0.383 |
|
| 2005 |
Ratliff TL. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. The Journal of Urology. 173: 1044. PMID 15711374 DOI: 10.1097/01.Ju.0000151873.27723.71 |
0.371 |
|
| 2005 |
Ratliff TL. Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. The Journal of Urology. 173: 1044-5. PMID 15711373 DOI: 10.1016/S0022-5347(05)60439-9 |
0.353 |
|
| 2005 |
Ratliff TL. In Vitro Efficacy of Fas Ligand Gene Therapy for the Treatment of Bladder Cancer Journal of Urology. 174: 1499-1499. DOI: 10.1097/S0022-5347(01)68690-7 |
0.349 |
|
| 2005 |
Ratliff TL. Immunotherapy for Superficial Bladder Cancer The Journal of Urology. 174: 1498-1499. DOI: 10.1097/S0022-5347(01)68689-0 |
0.323 |
|
| 2005 |
Ratliff TL. BMP Signals Inhibit Proliferation and In Vivo Tumor Growth of Androgen-Insensitive Prostate Carcinoma Cells The Journal of Urology. 173: 1825-1825. DOI: 10.1097/01.Ju.0000159586.83680.Ed |
0.447 |
|
| 2005 |
Ratliff TL. Systematic Evaluation of Genetic Variation at the Androgen Receptor Locus and Risk of Prostate Cancer in a Multiethnic Cohort Study The Journal of Urology. 173: 1826-1826. DOI: 10.1016/S0022-5347(05)60735-5 |
0.409 |
|
| 2005 |
Ratliff TL. Bone Morphogenetic Protein (BMP)-6 Signaling and BMP Antagonist Noggin in Prostate Cancer The Journal of Urology. 173: 1825-1825. DOI: 10.1016/S0022-5347(05)60734-3 |
0.39 |
|
| 2004 |
Ratliff TL. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report From the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee Journal of Urology. 172: 809-810. DOI: 10.1016/S0022-5347(05)61796-X |
0.455 |
|
| 2004 |
Ratliff TL. Sequence Variants of Toll-Like Receptor 4 are Associated With Prostate Cancer Risk: Results From the CAncer Prostate in Sweden Study Journal of Urology. 172: 2114-2114. DOI: 10.1016/S0022-5347(05)60992-5 |
0.453 |
|
| 2004 |
Ratliff TL. Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model Journal of Urology. 172: 2113-2114. DOI: 10.1016/S0022-5347(05)60991-3 |
0.461 |
|
| 2003 |
Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity. 19: 9-19. PMID 12871635 DOI: 10.1016/S1074-7613(03)00177-8 |
0.68 |
|
| 2003 |
Crist SA, Griffith TS, Ratliff TL. Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element. The Journal of Biological Chemistry. 278: 35950-8. PMID 12855690 DOI: 10.1074/Jbc.M306220200 |
0.306 |
|
| 2003 |
Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, Jocham D, Sczakiel G, Gerdes J, Böhle A. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. International Journal of Cancer. Journal International Du Cancer. 105: 710-6. PMID 12740923 DOI: 10.1002/Ijc.11111 |
0.396 |
|
| 2003 |
Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense & Nucleic Acid Drug Development. 12: 155-64. PMID 12162698 DOI: 10.1089/108729002760220752 |
0.487 |
|
| 2003 |
Siemens DR, Ratliff TL. Are Vaccinations for Prostate Cancer Realistic? Prostate Cancer: Science and Clinical Practice. 545-554. DOI: 10.1016/B978-012286981-5/50060-4 |
0.302 |
|
| 2002 |
Broghammer EL, Ratliff TL. Immunotherapy of urologic tumors: principles and progress. Urologic Oncology. 7: 45-56. PMID 12474522 DOI: 10.1016/S1078-1439(01)00151-X |
0.369 |
|
| 2002 |
Ratliff TL. Mast cell regulation of inflammation and gene expression during antigen-induced bladder inflammation in mice. The Journal of Urology. 168: 885. PMID 12136879 DOI: 10.1016/S0022-5347(05)64815-X |
0.34 |
|
| 2002 |
Ratliff TL. Robust prostate-specific expression for the targeted gene therapy based on the human kallikrein 2 promoter. The Journal of Urology. 168: 884. PMID 12136877 DOI: 10.1016/S0022-5347(05)64813-6 |
0.4 |
|
| 2002 |
Kausch I, Ardelt P, Böhle A, Ratliff TL. Immune gene therapy in urology. Current Urology Reports. 3: 82-9. PMID 12084224 DOI: 10.1007/S11934-002-0015-6 |
0.388 |
|
| 2001 |
Elzey BD, Robert Siemens D, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors International Journal of Cancer. 94: 842-849. PMID 11745487 DOI: 10.1002/Ijc.1556 |
0.505 |
|
| 2001 |
Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immmunoregulatory cells with recombinant canarypox viruses Journal of the National Cancer Institute. 93: 998-1007. PMID 11438565 DOI: 10.1093/Jnci/93.13.998 |
0.471 |
|
| 2001 |
Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Bhle A. NK cells are essential for effective BCG immunotherapy International Journal of Cancer. 92: 697-702. PMID 11340575 DOI: 10.1002/1097-0215(20010601)92:5<697::Aid-Ijc1245>3.0.Co;2-Z |
0.344 |
|
| 2001 |
Siemens DR, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, Swanson AK, Ratliff TL. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. Journal of Immunology (Baltimore, Md. : 1950). 166: 731-5. PMID 11145643 DOI: 10.4049/Jimmunol.166.2.731 |
0.335 |
|
| 2000 |
Siemens DR, Iwasawa T, Austin JC, Williams RD, See WA, Hedican SP, Tartaglia J, Flynn CM, Cohen MB, Rodgers J, Ratliff TL. Biomarker distribution after injection into the canine prostate: implications for gene therapy. Bju International. 86: 1076-83. PMID 11119105 DOI: 10.1046/J.1464-410X.2000.00865.X |
0.392 |
|
| 2000 |
Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 6244-51. PMID 11086059 DOI: 10.4049/Jimmunol.165.11.6244 |
0.325 |
|
| 2000 |
Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. Journal of Immunology (Baltimore, Md. : 1950). 165: 2886-94. PMID 10946322 DOI: 10.4049/Jimmunol.165.5.2886 |
0.319 |
|
| 2000 |
Norian LA, Latinis KM, Eliason SL, Lyson K, Yang C, Ratliff T, Koretzky GA. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 164: 4471-80. PMID 10779747 DOI: 10.4049/Jimmunol.164.9.4471 |
0.349 |
|
| 2000 |
Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL. Role of a bacillus calmette-guerin fibronectin attachment protein in BCG-induced antitumor activity International Journal of Cancer. 86: 83-88. PMID 10728599 DOI: 10.1002/(Sici)1097-0215(20000401)86:1<83::Aid-Ijc13>3.0.Co;2-R |
0.307 |
|
| 2000 |
Siemens DR, Austin JC, Hedican SP, Tartaglia J, Ratliff TL. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model Journal of the National Cancer Institute. 92: 403-412. PMID 10699070 DOI: 10.1093/Jnci/92.5.403 |
0.385 |
|
| 1999 |
Siemens DR, Austin JC, Hedican SP, Ratliff TL, Tartaglia J. Viral Delivery In A Gelatin Sponge Matrix Enhances Gene Expression And Antitumor Activity In A Murine Prostate Cancer Model The Journal of Urology. 61. DOI: 10.1097/00005392-199904010-00247 |
0.436 |
|
| 1999 |
Elzey D, Ratliff TL, Schlom J, Tartaglia J. Psa-Encoding Adenovirus Induces Potent Antitumor Immunity In A Mouse Prostate Tumor Model The Journal of Urology. 53. DOI: 10.1097/00005392-199904010-00214 |
0.471 |
|
| 1999 |
Chan DW, Kelley CA, Ratliff TL, D’Agostino D, Ritchey J, Lamb DJ, Beck J, Lott N, Wener MH, Daum P, Henkin RE, Kaske DN, Golightly DW, McBride J, Layco G, et al. Analytical and Clinical Performance Characteristics of Hybritech’s Tandem-R free PSA Assay during a Large Multicenter Clinical Trial to Determine the Clinical Utility of Percentage of Free Prostate-specific Antigen Clinical Chemistry. 45: 1863-1865. DOI: 10.1093/Clinchem/45.10.1863 |
0.435 |
|
| 1997 |
Keetch DW, Andriole GL, Ratliff TL, Catalona WJ. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting Urology. 50: 901-905. PMID 9426721 DOI: 10.1016/S0090-4295(97)00453-6 |
0.342 |
|
| 1997 |
Arcangeli CG, Smith DS, Ratliff TL, Catalona WJ. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. The Journal of Urology. 158: 2182-7. PMID 9366340 DOI: 10.1016/S0022-5347(01)68191-6 |
0.445 |
|
| 1997 |
Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. The Journal of Urology. 157: 2179-82. PMID 9146610 DOI: 10.1016/S0022-5347(01)64708-6 |
0.415 |
|
| 1997 |
Kawakita M, Rao GS, Ritchey JK, Ornstein DK, Hudson MA, Tartaglia J, Paoletti E, Humphrey PA, Harmon TJ, Ratliff TL. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth Journal of the National Cancer Institute. 89: 428-436. PMID 9091644 DOI: 10.1093/Jnci/89.6.428 |
0.404 |
|
| 1997 |
Ornstein DK, Rao GS, Smith DS, Ratliff TL, Basler JW, Catalona WJ. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. The Journal of Urology. 157: 195-8. PMID 8976249 DOI: 10.1016/S0022-5347(01)65321-7 |
0.463 |
|
| 1996 |
Ratliff TL, Kawakita M, Tartaglia J, Paoletti E. Canary-pox (ALVAC) virus-mediated cytokine gene therapy induces tumour specific and non-specific immunity against mouse prostate tumor Acta Urologica Belgica. 64: 85. PMID 8701820 |
0.332 |
|
| 1996 |
Ratliff TL. Editorial Comment: Urinary Cytokines during Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer The Journal of Urology. 482. DOI: 10.1097/00005392-199602000-00017 |
0.321 |
|
| 1996 |
Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Clinical Urology: Letter to the EditorIn Reply: Re: Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves The Journal of Urology. 155. DOI: 10.1016/S0022-5347(01)66289-X |
0.455 |
|
| 1995 |
Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. The American Journal of Pathology. 147: 386-96. PMID 7639332 |
0.351 |
|
| 1995 |
Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Jama. 274: 1214-20. PMID 7563511 DOI: 10.1001/Jama.1995.03530150038031 |
0.46 |
|
| 1995 |
Dalkin BL, Ahmann FR, Kopp JB, Catalona WJ, Ratliff TL, Hudson MA, Richie JP, Scardino PT, Flanigan RC, Dekernion JB, Waters WB, Kavoussi LR, MacFarlane MT. Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma British Journal of Urology. 76: 346-350. PMID 7551844 DOI: 10.1111/J.1464-410X.1995.Tb07712.X |
0.411 |
|
| 1995 |
Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. The Journal of Urology. 154: 407-13. PMID 7541857 DOI: 10.1016/S0022-5347(01)67064-2 |
0.472 |
|
| 1995 |
Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC, Hudson MA, Scardino PT, Flamigan RC, Waters WB. In Reply: Re Comparison of Prostate Specific Antigen Concentration Versus Prostate Specific Antigen Density in the Early Detection of Prostate Cancer Receiver Operating Characteristic Curves; Re Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer Receiver Operating Characteristic Curves The Journal of Urology. 154: 1145-1146. DOI: 10.1016/S0022-5347(01)67013-7 |
0.468 |
|
| 1994 |
Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis Journal of Urology. 152: 247-250. PMID 8201676 DOI: 10.1016/S0022-5347(17)32871-9 |
0.47 |
|
| 1994 |
Swerdlow RD, Ratliff TL, La Regina M, Ritchey JK, Ebert RF. Immunotherapy with keyhole limpet hemocyanin: Efficacy and safety in the MB-49 intravesical murine bladder tumor model Journal of Urology. 151: 1718-1722. PMID 8189604 DOI: 10.1016/S0022-5347(17)35352-1 |
0.317 |
|
| 1994 |
Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves Journal of Urology. 152: 2037-2042. PMID 7525995 DOI: 10.1016/S0022-5347(17)32300-5 |
0.438 |
|
| 1994 |
Catalona WJ, Richie JP, DeKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves Journal of Urology. 152: 2031-2036. PMID 7525994 DOI: 10.1016/S0022-5347(17)32299-1 |
0.445 |
|
| 1994 |
Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer Journal of Urology. 152: 1506-1509. PMID 7523707 DOI: 10.1016/S0022-5347(17)32457-6 |
0.449 |
|
| 1994 |
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men Journal of Urology. 151: 1283-1290. PMID 7512659 |
0.348 |
|
| 1993 |
Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL. Characterization of the internalization of Bacillus Calmette-Guerin by human bladder tumor cells Journal of Clinical Investigation. 91: 69-76. PMID 8423234 DOI: 10.1172/Jci116202 |
0.363 |
|
| 1993 |
Goldstein DS, Lu ML, Hattori T, Ratliff TL, Loughlin KR, Kavoussi LR. Inhibition of peritoneal tumor-cell implantation: Model for laparoscopic cancer surgery Journal of Endourology. 7: 237-241. PMID 8358421 DOI: 10.1089/End.1993.7.237 |
0.317 |
|
| 1993 |
Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer Journal of Urology. 150: 1018-1023. PMID 8102183 DOI: 10.1016/S0022-5347(17)35678-1 |
0.341 |
|
| 1993 |
Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, Dekernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination Urology. 42: 365-374. PMID 7692657 DOI: 10.1016/0090-4295(93)90359-I |
0.412 |
|
| 1993 |
Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. Jama. 270: 948-54. PMID 7688438 DOI: 10.1001/Jama.1993.03510080052031 |
0.463 |
|
| 1992 |
Bullock AD, Becich MJ, Klutke CG, Ratliff TL. Experimental autoimmune cystitis: A potential murine model for ulcerative interstitial cystitis Journal of Urology. 148: 1951-1956. PMID 1433651 DOI: 10.1016/S0022-5347(17)37091-X |
0.309 |
|
| 1992 |
Ratliff TL. Role of the immune response in BCG for bladder cancer European Urology. 21: 17-21. PMID 1396942 DOI: 10.1159/000474916 |
0.361 |
|
| 1992 |
Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, Catalona WJ. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. The Journal of Urology. 147: 810-4. PMID 1371553 DOI: 10.1016/S0022-5347(17)37392-5 |
0.437 |
|
| 1991 |
Becich MJ, Carroll S, Ratliff TL. Internalization of bacille calmette-guerin by bladder tumor cells Journal of Urology. 145: 1316-1324. PMID 2033723 DOI: 10.1016/S0022-5347(17)38622-6 |
0.358 |
|
| 1991 |
Coplen DE, Brown EJ, McGarr J, Ratliff TL. Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24 Journal of Urology. 145: 1312-1315. PMID 2033722 DOI: 10.1016/S0022-5347(17)38621-4 |
0.315 |
|
| 1991 |
Ratliff TL. Bacillus Calmette-Guerin (BCG): Mechanism of action in superficial bladder cancer Urology. 37: 8-11. PMID 2021034 DOI: 10.1016/0090-4295(91)80127-S |
0.306 |
|
| 1991 |
Kiser WR, Clark CA, Klotz L, Braun MM, Teutsch SM, Coney R, Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen as a screening test for prostate cancer [1] New England Journal of Medicine. 325: 963-965. PMID 1715514 DOI: 10.1056/NEJM199109263251313 |
0.358 |
|
| 1991 |
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. The New England Journal of Medicine. 324: 1156-61. PMID 1707140 DOI: 10.1056/Nejm199104253241702 |
0.485 |
|
| 1990 |
Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response Journal of Clinical Investigation. 85: 62-67. PMID 2404029 DOI: 10.1172/Jci114434 |
0.338 |
|
| 1990 |
Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors Journal of Urology. 144: 1362-1364. PMID 2231927 DOI: 10.1016/S0022-5347(17)39741-0 |
0.301 |
|
| 1990 |
Bahnson RR, Ratliff TL. In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2) Journal of Urology. 144: 172-175. PMID 2113589 DOI: 10.1016/S0022-5347(17)39404-1 |
0.315 |
|
| 1988 |
Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer Journal of Urology. 139: 941-944. PMID 3361668 DOI: 10.1016/S0022-5347(17)42723-6 |
0.304 |
|
| 1987 |
Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Gurerin therapy for superficial bladder cancer Journal of Urology. 137: 220-224. PMID 3806806 DOI: 10.1016/S0022-5347(17)43959-0 |
0.314 |
|
| 1987 |
Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity Journal of Urology. 137: 155-158. PMID 3491909 DOI: 10.1016/S0022-5347(17)43909-7 |
0.339 |
|
| 1987 |
Ratliff TL. Intravescial Bacille Calmette Guerin (BCG) Therapy for Murine Bladder Tumors: Initiation of the Response by Fibronectin-Mediated Attachment of BCG Journal of Urology. 137. DOI: 10.1016/S0022-5347(17)75316-5 |
0.306 |
|
| 1986 |
Lage JM, Bauer WC, Kelley DR, Ratliff TL, Catalona WJ. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer Journal of Urology. 135: 916-919. PMID 3959240 DOI: 10.1016/S0022-5347(17)45922-2 |
0.399 |
|
| 1986 |
Ratliff TL, Shapiro A, Catalona WJ. Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: Lack of a role of natural killer cells Clinical Immunology and Immunopathology. 41: 108-115. PMID 3527506 DOI: 10.1016/0090-1229(86)90055-3 |
0.32 |
|
| 1985 |
Fleischmann J, Heston WD, Bander NH, Bauer WC, Janney C, Ratliff TL, Fair WR. Human renal cell carcinoma xenograft: morphology, growth and chemosensitivities. The Journal of Urology. 134: 570-4. PMID 3928905 DOI: 10.1016/S0022-5347(17)47302-2 |
0.31 |
|
| 1985 |
Haff EO, Dresner SM, Kelley DR, Ratliff TL, Shapiro A, Catalona WJ. Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review World Journal of Urology. 3: 76-85. DOI: 10.1007/Bf00326713 |
0.313 |
|
| 1982 |
Ratliff TL, MacDermott RP, Poepping NJ, Oakley DM, Shapiro A, Catalona WJ. Production of gamma interferon by human T and null cells and its regulation by macrophages Cellular Immunology. 74: 111-119. PMID 6819089 DOI: 10.1016/0008-8749(82)90011-9 |
0.322 |
|
| 1982 |
Shapiro A, Kadmon D, Catalona WJ, Ratliff TL. Immunotherapy of superficial bladder cancer Journal of Urology. 128: 891-894. PMID 6184490 DOI: 10.1016/S0022-5347(17)53265-6 |
0.315 |
|
| 1981 |
Catalona WJ, Ratliff TL, McCool RE, Heston WDW. Role of antibody in cytotoxicity by lymphocytes armed against 253j bladder cancer line International Archives of Allergy and Immunology. 66: 259-266. PMID 7298218 DOI: 10.1159/000232829 |
0.312 |
|
| 1980 |
Catalona WJ, Ratliff TL, McCool RE. Concanavalin A-activated suppressor cell activity in peripheral blood lymphocytes or urologic cancer patients Journal of the National Cancer Institute. 65: 553-557. PMID 6157855 DOI: 10.1093/Jnci/65.3.553 |
0.366 |
|
| 1979 |
Ratliff TL, McCool RE, Catalona WJ. Antibody-dependent and spontaneous lympholysis in urologic cancer patients. British Journal of Cancer. 39: 667-75. PMID 444405 DOI: 10.1038/Bjc.1979.118 |
0.357 |
|
| 1978 |
Catalona WJ, Ratliff TL, McCool RE. Effects of carrageenan on spontaneous and antibody-dependent cell-mediated cytotoxicity Cellular Immunology. 40: 1-15. PMID 568037 DOI: 10.1016/0008-8749(78)90310-6 |
0.327 |
|
| Show low-probability matches. |